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Background: The aim of this study was to evaluate the relationship between changes in 
proton magnetic resonance spectroscopy (1H-MRS) parameters at the start of the index 
episode recovery phase and at recurrence in patients with recurrent depression who 
were treated with prolonged maintenance therapy.
Methods: 1H-MRS parameters were analyzed in 48 patients with recurrent depression 
who required maintenance therapy with antidepressant medication prescribed by a 
psychiatrist and who continued with the same antidepressant during the maintenance 
phase, either to recurrence of depression, completion of the 10-year observation period, 
or the start of the withdrawal phase (tapering-off antidepressant). N-acetylaspartate 
(NAA), choline-containing metabolites (Cho), creatine (Cr), and glutamine/glutamate 
were measured at the start of the recovery phase and 6 months later.
results: Recurrent depressive episodes occurred in 20 patients. These individuals had 
a smaller increase in Cho/Cr after the beginning of the recovery phase compared to the 
non-recurrent patient group and also exhibited a decreased NAA/Cr ratio.
conclusion: Sustainable NAA and increased Cho levels at the onset of the recovery 
phase of the index episode are early markers of antidepressant effectiveness associated 
with a lower risk of major depressive disorder recurrence. The NAA and Cho changes in 
the non-recurrent group may be attributable to increased brain resilience, contrary to the 
transient temporal effect observed in subjects who experienced a depressive episode.
Keywords: depression, recurrence, maintenance therapy, antidepressants, magnetic resonance spectroscopy
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inTrODUcTiOn
Approximately 35% of depressed patients experience a recur-
rent episode. The longitudinal course includes an active phase, 
which is followed by remission and recovery phases. A patient 
is considered to be in remission after 3 consecutive weeks of 
maintaining minimal symptom status. They are in recovery, if 
a relapse does not occur for at least 4  months followed by the 
onset of remission. Recovery, once achieved, is lost if followed 
by a recurrence (1). In a 10-year follow-up study, the risk of the 
recurrence of major depressive disorder (MDD) progressively 
increased with each successive episode. The risk fell as time 
without recurrence elapsed, whereas the within-subject time to 
recurrence varies considerably from one recurrence to the other 
(2). Other identified risk factors for recurrence include family 
history of recurrent depression, previous history of dysthymic 
disorder, early onset, and residual depressive symptoms (3). After 
three episodes, the risk of recurrence approaches 100% in the 
absence of prophylactic treatment; patients who have had three 
or more prior major depressive episodes should proceed to the 
maintenance phase of therapy after completing the continuation 
phase (3). Antidepressants should be prescribed at the full thera-
peutic dose who achieved symptom remission during the acute 
and continuation phases. Patients should be monitored at regular 
intervals using standardized measurement aids to facilitate early 
detection of recurrent symptoms.
In larger studies, the average episode duration ranges from 16 
to 24.3 weeks (4, 5). With regard to pharmacotherapies, a meta-
analysis of 102 studies found no overall difference in efficacy 
between selective serotonin reuptake inhibitors (SSRIs) and 
tricyclic antidepressants (TCAs) (4).
Proton magnetic resonance spectroscopy (1H-MRS) evaluates 
brain metabolites in vivo and could improve our understanding of 
molecular and submolecular changes in the brain. The 1H-MRS 
technique is based on the fact that different molecules possess 
unique magnetic resonance (MR) spectra, and their quantities 
can be measured against standard metabolite curves. Among the 
spectroscopic techniques, proton spectroscopy is the most widely 
used due to its high sensitivity, distinguishable spectra, high 
signal-to-noise ratio, and ease of use as this technique can be per-
formed using standard radiofrequency coils (5). Neurochemicals 
and complexes identified by 1H-MRS, include N-acetylaspartate 
(NAA), creatine (Cr), choline-containing metabolites (Cho), 
glutamine/glutamate (Glx), myoinositol, glycine, glucose, lipids, 
lactate, alanine, acetate, succinate, and taurine.
Since NAA is found in neurons, but not in glial cells or blood, 
it is considered a putative marker of neuronal integrity (6) and 
functionality (7, 8). Several studies have shown altered NAA 
levels following antidepressant treatment. Increased NAA/Cr 
ratios were reported in the prefrontal cortex (PFC) and frontal 
white matter after SSRI therapy (9), as well as in the hippocampus 
(10). Another group reported higher NAA in the left medial 
frontal cortex of depressed patients after treatment with SSRIs 
and serotonin–norepinephrine reuptake inhibitors (11). NAA 
changes were observed even after just 7  days of treatment (9). 
A voxel-based morphometric study (12) reported reduced gray 
matter volume in the left dorsolateral prefrontal cortex (DLPFC) 
of non-remitting MDD patients, and another group concluded 
that a longer history of depression correlates with lower NAA 
values (13). Collectively, these results support the hypothesis that 
illness chronicity leads to neurodegenerative processes in the 
DLPFC.
Glycerophosphocholine (GPC) and phosphocholine (PC) 
represent over 50% of cytosolic Cho-containing compounds 
in the living brain (14, 15). As PC is a precursor of membrane 
phospholipids and GPC is a breakdown product (16), Cho 
is considered a potential marker of membrane phospholipid 
metabolism and membrane turnover. Increased Cho/Cr ratios 
in the bilateral ventral prefrontal white matter of MDD patients 
was documented after 12 weeks of SSRI treatment (17). We previ-
ously reported a higher Cho/Cr ratio in the absence of any change 
in NAA/Cr in the DLPFC in early-to-intermediate responders 
after 3–6 weeks of SSRI treatment for recurrent depression and 
comorbid posttraumatic stress disorder (18). The increase of Cho 
in therapy responders does not seem to be medication specific, 
as the increase is also observed in PFC after sleep restriction (19) 
and repetitive transcranial magnetic stimulation (20).
Research of glutamine, glutamate, and gamma-aminobutyric 
acid (GABA) metabolites, usually combined in a Glx peak, is 
based on the observation of GABAergic dysfunction in depressed 
subjects who have low plasma and cerebrospinal fluid GABA 
concentrations (21). A meta-analysis reported a reduction in 
absolute Glx values in the PFC of patients with depression, cor-
relating with disease severity (22). GABA levels in MDD patients 
are also lower, but normalize following antidepressant treatment 
(23), so remitted MDD patients do not have significantly different 
values from controls (24).
The DLPFC is a particular region of interest (ROI) since neu-
roimaging, lesion analysis, postmortem, histopathological, and 
genomic studies have consistently indicated abnormalities in this 
brain area of depressed patients, whereas hyperactivity has been 
reported in the DLPFC during the recovery phase in response to 
medication (25). A recent review emphasized the need for further 
research of the DLPFC and other frontal regions over a longer 
period, to establish the functional relevance of Cho metabolites 
in the treatment of MDD (26).
The aim of this study was to evaluate the relationship between 
changes in 1H-MRS parameters at the start of the index episode 
recovery phase, and during recurrence in patients suffering 
from recurrent depression, who were prescribed maintenance 
therapy. Our approach is unique in that we correlated changes in 
1H-MRS parameters coincident with the recovery period with 
clinical outcomes. Based on the literature on changes in 1H-MRS 
parameters over the course of treatment, we hypothesized that 
patients who maintained stable condition (i.e., begun tapering-
off medication without a recurrence) would exhibit differences in 
Cho levels and possibly also in NAA and Glx ratios.
MaTerials anD MeThODs
This was a retrospective cohort study. Among patients who 
previously participated in the past research into predictors of 
therapeutic response, we identified 48 patients who had MRS 
scans of the DLPFC at the start of the recovery period and 
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6 months later. The primary goal of this study was to describe 
MRS metabolite changes between the time of the recovery and 
after 6 months, but the results were inconclusive and considered 
inappropriate for publication. The MDD patients included in 
this study had no history of comorbid psychiatric disorders. 
Diagnoses of depression and recurrent depression were based on 
International Classification of Diseases (ICD)-10 diagnostic cri-
teria and were confirmed by Mini International Neuropsychiatric 
Interview (MINI) 5.0 (27). A comorbid diagnosis of somatic 
illness was the exclusion criterion. This study was approved by 
the institutional ethics committee, and this study protocol was 
formulated in accordance with the Declaration of Helsinki. Prior 
to their inclusion, patients had already consented to participate in 
long-term evaluations that would include psychiatric interviews 
and assessments. Both were performed at least every 6 months 
(and occasionally even more frequently, as patients opted for 
regular visits due to local formal procedures requiring a patient to 
attend a psychiatric evaluation to obtain prescriptions within the 
obligatory health insurance scheme). Throughout the study, all 
patients were treated on an outpatient basis. Monotherapy with 
antidepressants and a stable dose of medication from the ben-
zodiazepine class, if used, was set as an inclusion criterion when 
recovered patients were selected for the MRS study. Patients were 
treated only with pharmacotherapy during the research period. 
Psychotherapy and any other therapy methods were not used.
The choice of antidepressant medication was left to the prac-
titioner treating the patient, and no conditions were set either 
with regard to the need for changing the antidepressant or the 
therapy duration. Participants were prescribed antidepressants 
according to the Summary of Product Characteristics of the 
individual medication. Baseline evaluation was performed at the 
first contact with the patient in relation to the current episode, 
after the patient consented to participate in this study. Definitions 
of remission and recovery were based on the standard criterion 
of a Montgomery–Asberg Depression Scale (MADRS) score ≤10. 
MRS scanning in the recovery phase was performed the same day 
as the clinical evaluation or 2 days after at the latest and at least 
4 months after the onset of remission, when the MADRS score 
was ≤10.
Patients were followed up either until the beginning of the 
tapering phase of the antidepressant medication or to the emer-
gence of recurrent depression symptoms. In addition to regular 
psychiatric assessments, regular 6-month follow-ups included 
MADRS scale evaluation. We use the term “withdrawal” in 
this study to indicate the first time point in the maintenance 
period when the dose of antidepressant medication was changed 
(tapered) with the intent to completely discontinue medication 
treatment. The withdrawal phase starts at this time point, and the 
future course of illness is beyond the scope of this study.
The schematic study is displayed in Figure 1.
1h-Mrs analyses
Proton magnetic resonance spectroscopy data acquisition was 
performed using a 2.0  T system (Gyrex 2T-Prestige, GEMS/
Elscint, Haifa, Israel) with a quadrate head coil. The subject was 
in a supine position, with the intersection of the frontal bone 
and two nasal bones (nasion) serving as a landmark. Foam pads 
were used to minimize head motion. Voxels were placed for 
spectroscopy, and all data analyses were performed by a trained 
radiologist blinded to the subjects’ diagnoses. Standard T1 and 
T2 sequences completed in the coronal, sagittal, and axial planes 
and covering the entire brain were acquired for each subject to 
assess the effect of spectral localization and exclude possible 
structural brain damage. The voxels were repositioned in the 
ROI of the left DLPFC. The spectroscopic volume of interest, 
15  mm ×  15  mm ×  15  mm, was selected in the left DLPFC 
region to minimize the amount of cerebrospinal fluid contained 
in the volume of interest. 1H-MRS was performed using a point-
resolved spectroscopy sequence (1,500/35 [repetition time/echo 
time]), with 100 averages. Each spectrum was re-evaluated for 
peak NAA (at 2.02 ppm), Cho (at 3.2 ppm), Glx (at 2.2–2.4 ppm), 
and Cr (at 3.03 ppm). The absolute NAA, Cho, and Glx values 
and their ratios to Cr were used for the analyses. Analyses of 
the spectral dataset were performed using the software package 
program supplied by the manufacturer of the MR system (Gyrex 
2T-Prestige, GEMS/Elscint).
statistical analysis
Statistical analysis was performed with the Statistica software 
package, version 13.2 (Dell Inc., Austin, TX, USA). The level of 
statistical significance was set to 0.05 for all analyses. The hypoth-
esis in relation to power analysis was that groups would differ 
in Cho/Cr changes between the start of recovery period and the 
6-month follow-up. With estimated between group differences in 
Cho/Cr ratio changes of 0.05 and a SD of 0.1, where α = 0.05, a 
sample size of 43 with 1.15 sampling ratio would achieve power 
(1 − β) of 0.67. Before performing any analyses, the normality 
of distribution of continuous variables was assessed with both 
Kolmogorov–Smirnov and Shapiro–Wilk tests. Differences 
between the two subject groups were first analyzed by means 
of Student’s t-tests or Mann–Whitney U tests. Differences in 
categorical variables were assessed with χ2 tests.
Descriptive statistics are displayed for 43 subjects who either 
experienced a recurrent episode on maintenance therapy (20 
subjects) or entered the withdrawal phase. Five remaining 
patients were excluded from descriptive analyses, since the future 
direction of change of their remission is unknown (two patients 
were lost to further follow-up) or were assessed at the 6-month 
follow-up after the recovery phase and later received in-patient 
treatment (two bipolar patients and one patient with serotonergic 
syndrome). However, final observations from those five patients 
are useful for survival estimations and their observations were 
entered into the analysis as censored cases.
All cases except those with documented episodes that occur-
red after the index episodes are censored. The most frequent 
reason was the initiation of maintenance therapy withdrawal. 
In that group, it would not be prudent to record the possible 
later onset of the episode as the one that occurred under main-
tenance therapy, since the maintenance antidepressant dose 
was already decreased, if not completely withdrawn, prior to 
the episode.
We employed Cox proportional hazard (CPH) analysis using a 
forward stepwise likelihood ratio model to assess neurochemical 
brain changes as prognostic risk factors for depression recurrence. 
FigUre 1 | Study schematic.
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The prognostic factors to be entered into CPH analysis involved 
brain metabolites in the DLPFC, those based on current knowl-
edge regarding the recurrence of depressive episodes under 
maintenance therapy, and the set of factors we assumed might 
modify metabolite levels. The initial set of variables includes post-
recovery changes in NAA/Cr, Cho/Cr, and Glx/Cr metabolites 
as our primary variables of interest, as well as the time elapsed 
between remission and baseline, age at first episode onset, years 
of depression, the number of prior depressive episodes, MADRS 
score at baseline, improvement on MADRS score at recovery, and 
MADRS score change between recovery and 6-month follow-up. 
The baseline MADRS score was highly correlated with improve-
ment in MADRS score at recovery (r =  0.96), so we only kept 
MADRS improvement at recovery in the model.
The model entered into the CPH analysis initially consisted 
of three MRS metabolites, three variables describing the course 
of a current episode (time to remission, MADRS improvement 
at recovery, and change in the MADRS score between recovery 
and 6-month follow-up), and three variables describing the past 
course of recurrent depressive disorder (age at the onset of the 
first episode, years of depression, and number of prior episodes).
After identifying the CPH model that contained param-
eters with significant contributions, we developed a model with 
dichotomized variables in which we analyzed the overall direc-
tion of change in neurometabolites (<0 vs. ≥0), but not the extent 
of their rise or fall. We considered that this dichotomized model 
would enable easier interpretation and allow for the identification 
of significant concomitant changes in brain metabolites in rela-
tion to prognostic risk.
resUlTs
Forty-eight subjects were included in our study and were 
evaluated by 1H-MRS scans of the DLPFC at the start of their 
recovery period and 6 months later. Among these, 43 were fol-
lowed up at regular 6-month intervals either to the recurrence 
of another depressive episode or until entering the medication 
tapering-off period. The remaining five subjects lacked consistent 
data until those end points, as they were either lost to follow-up 
(two patients), converted to bipolar disorder (two patients), or 
abruptly stopped medication due to an adverse event (serotoner-
gic syndrome in one patient).
FigUre 2 | MRS measurements of NAA/Cr. (____)  Followed-up until 
recurrence of depressive episode. (-----) Followed-up until start of 
antidepressant medication withdrawal. Horizontal axis: 1 – Start of the 
recovery phase; 2 – Start of the recovery phase + 6 months. Error bars 
denote 95%CI of means. *p < 0.005 t-test.
TaBle 1 | Descriptors of courses of disorder and the current episode.
Withdrawal 
started
recurrence of 
an episode
n = 23 n = 20
Variable Mean sD Mean sD p
Years to event
Withdrawal 3.03 1.67
Recurrence 1.63 0.88 0.0017
Disorder course descriptors
Age at onset of disorder 28.21 7.75 27.59 8.98 0.8088
Years of depression 16.27 10.15 15.99 11.13 0.9328
No. of prior episodes 3.78 1.73 4.00 2.41 0.7332
current episode descriptors
Months to remission 5.93 1.40 5.81 1.65 0.7945
MaDrs score
At the beginning of an episode 25.79 4.13 25.90 4.07 0.9305
At the start of the recovery phase 5.40 1.33 5.61 1.07 0.5696
6 months after the start  
of the recovery phase
5.55 0.88 5.29 1.41 0.4575
At the visit prior to  
the last evaluation
5.34 1.10 5.44 1.27 0.7733
at the last evaluation
Withdrawal 5.32 0.87
Recurrence 20.30 1.44 <0.0001
MADRS, Montgomery–Asberg Depression Scale.
Withdrawal-first time point over study when antidepressant medication was tapered 
with the intention to discontinue medication.
TaBle 2 | Changes in 1 H-MRS metabolite levels from the time of recovery to 
6 months later.
Withdrawal  
started
recurrence of an 
episode
n = 23 n = 20
Metabolite Mean sD Mean sD p*
Cho/Cr 0.0860 0.0962 0.0250 0.1231 0.076
NAA/Cr 0.0972 0.2040 –0.0380 0.2155 0.041
Glx/Cr 0.0159 0.1958 0.0459 0.2690 0.676
*Two-sided t-test for independent samples.
Cho, choline-containing metabolites; Cr, creatine; Glx, glutamate/glutamine; 1H-MRS, 
proton magnetic resonance imaging; NAA, N-acetylaspartate.
Withdrawal was the first time point over when antidepressant medication was tapered 
with the intention to discontinue medication.
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In total, 30 female and 18 male patients were included. 
Eleven (55%) female patients experienced another depressive 
episode while on maintenance therapy, and 15 (65.2%) entered 
the tapering-off period. The group of patients for which the 
resolution of maintenance therapy is not known consists 
predominantly of female patients (four females out of five 
patients). At the beginning of an index episode, the average 
age of patients who would later experience recurrence was 
43.6  years (SD =  11.6), while the mean age of patients who 
started a withdrawal and did not experience subsequent epi-
sode was 44.5 years (SD = 13.2). No gender (χ2 = 0.47; d.f. = 1; 
p = 0.49) or age differences (t = 0.23; d.f. = 41; p = 0.82) were 
observed between the two groups. The most distant end point 
to which any patient was monitored was 6.9 years, considerably 
below the 10-year targets.
Patients who have entered the withdrawal phase were in the 
study nearly twice as long as those who experienced a subse-
quent episode during the study period (3.0 years; SD = 1.7 vs. 
1.6 years; SD = 0.9; p = 0.0017), which is expected in a study 
of this type where patients experiencing the event are moved 
to the uncensored group. Another expected difference was the 
imbalance in depression severity at the last observation when 
all uncensored subjects were found to have worsening symp-
toms. However, that visit immediately preceded the diagnosis 
of a recurrent episode, so both groups had similar symptom 
severity (MADRS scores of 5.3; SD =  1.1 vs. 5.4; SD =  1.3), 
as displayed in Table  1. The groups were comparable by all 
other analyzed descriptors of disorder course and the current 
episode.
Analyzed 1H-MRS metabolite levels are characterized by 
two features in patients who experienced a recurrent depressive 
episode: a significant rise in NAA/Cr and even more pronounced 
rise in Cho/Cr (Figure 2). We observed an opposite direction of 
NAA/Cr change in patients with a recurrent episode (t = 2.11; 
d.f. = 41; p = 0.041) compared to those who remained in remis-
sion (Table 2). The change in Cho/Cr was more than threefold 
lower in patients who experienced a recurrent episode (t = 1.82; 
d.f. = 41; p = 0.076) (Figure 3). There was also nearly a three-
fold higher change in Glx/Cr in this group (t = –0.42; d.f. = 41; 
p = 0.676), but due to the high coefficient of variability, the result 
was not statistically significant (Figure 4).
For every variable in the CPH analysis, we verified the pro-
portional hazard assumption by constructing a product between 
the variable and a linear function of time, added an interaction 
term, and tested for its significance. This step was done to confirm 
that a time-varying effect was not present, as its existence would 
discredit the use of a CPH model and indicate that observed 
metabolite changes are correlates of an episode that has begun 
to neurochemically develop, but is not yet clinically manifested. 
None of the time-dependent covariates were significant. To 
assess the proportionality assumption, we also inspected a plot 
of the log–og[S(t)] functions and visually confirmed constant 
hazard ratios.
First, we evaluated the initial model which, in addition to 
neurometabolites of our interest, included variables from the 
TaBle 3 | Parameter estimates of the initial model.
Factor relative risk (95% 
confidence interval)
p
1h-Mrs metabolite changes  
6 months after recovery
NAA/Cr 0.0639 (0.0062–0.6602) 0.0210
Cho/Cr 0.0077 (0.0001–0.5269) 0.0240
Glx/Cr 0.5544 (0.0744–4.1307) 0.5648
current episode descriptors
Months to remission 0.9031 (0.6171–1.3215) 0.5996
MADRS improvement at recovery 1.1034 (0.9664–1.2598) 0.1458
MADRS change 6 months after recovery 0.9378 (0.6637–1.3252) 0.7160
Disorder course descriptors
Age at onset 0.993 (0.9299–1.0604) 0.8332
Years of depression 0.9644 (0.9036–1.0294) 0.2760
No. of prior episodes 1.116 (0.8407–1.4816) 0.4477
Cho, choline-containing metabolites; Cr, creatine; Glx, glutamate/glutamine;  
1H-MRS, proton magnetic resonance imaging; MADRS, Montgomery–Asberg 
Depression Scale; NAA, N-acetylaspartate.
Withdrawal was the first time point over when antidepressant medication  
was tapered with the intention to discontinue medication.
TaBle 4 | Parameter estimates of the final model.
Factor relative risk (95% 
confidence interval)
p
1h-Mrs metabolite changes 
6 months after recovery
NAA/Cr 0.1541 (0.0247–0.9628) 0.0455
Cho/Cr 0.0063 (0.0001–0.4178) 0.0179
after dichotomization (only rise or 
fall monitored) 1h-Mrs metabolite 
changes 6 months after recovery
Cho/Cr remains equal or rises 1.0000
Cho/Cr decreases 2.7383 (1.1233–6.6752) 0.0267
Cho, choline-containing metabolites; Cr, creatine; 1H-MRS, proton magnetic 
resonance imaging; NAA, N-acetylaspartate.
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FigUre 4 | MRS measurements of Glx/Cr. (____)  Followed-up until 
recurrence of depressive episode. (-----) Followed-up until start of 
antidepressant medication withdrawal. Horizontal axis: 1 – Start of the 
recovery phase; 2 – Start of the recovery phase + 6 months. Error bars 
denote 95%CI of means.
dichotomized model consists of Cho/Cr decrease after remission 
as a highly predictive variable for depression recurrence. The 
results indicate that patients with decreased Cho/Cr after remis-
sion have a 2.7-fold higher risk of experiencing recurrence than 
patients in whom Cho/Cr ratio is stable or increased.
Escitalopram was the most frequently used antidepressant in 
both groups (five in the group of patients resolving with with-
drawal, six in the recurrent episode group). Other antidepres-
sants used in the group that started tapering off were fluoxetine 
(four patients), sertraline (4), venlafaxine (3), amitryptiline (2), 
reboxetine (1), citalopram (1), fluvoxamine (1), paroxetine (1), 
and mirtazapine (1). Other antidepressants used by patients who 
experienced a recurrent episode were sertraline (5), mirtazapine 
(2), fluoxetine (1), venlafaxine (1), reboxetine (1), citalopram (1), 
fluvoxamine (1), paroxetine (1), and imipramine (1).
Overall, the MADRS score significantly improved from the 
beginning of an episode to the start of the recovery phase, with 
no difference between patients who experienced a recurrent 
episode (20.3; SD = 4.1) and those who entered the withdrawal 
phase (20.4; SD = 3.8; p = 0.93). At the 6-month follow-up period, 
MADRS changes were only minor: (0.2; SD = 1.7) on average in 
FigUre 3 | MRS measurements of Cho/Cr. (____)  Followed-up until 
recurrence of depressive episode. (-----) Followed-up until start of 
antidepressant medication withdrawal. Horizontal axis: 1 – Start of the 
recovery phase; 2 – Start of the recovery phase + 6 months. Error bars 
denote 95%CI of means. **p < 0.001 t-test.
literature seen as the basic indicators of the severity and longitu-
dinal course of the current episode and as likely to increase the 
risk of recurrence. Parameter estimates of the initial model are 
presented in Table 3.
Inspection of beta coefficients, risk ratios with their 95% 
confidence intervals (CIs), t-value approximations, and Wald 
statistics of nine variables entered into the CPH model indicated 
significant contributions of only two variables: changes in NAA/
Cr and Cho/Cr. This was further confirmed when those nine 
variables were entered into the CPH forward stepwise likelihood 
ratio model, which consisted of two steps. After the inclusion 
of Cho/Cr change at the first step [B  =  –4.812; SE  =  2.041; 
Wald =  5.559; d.f. =  1; p =  0.018; Exp(B) =  0.008], the final 
model (–2 log likelihood = 125.64; χ2 = 10.1; d.f. = 2; p = 0.006) 
consists of two variables: Cho/Cr change [B = –5.075; SE = 2.144; 
Wald = 5.604; d.f. = 1; p = 0.018; Exp(B) = 0.006] and NAA/Cr 
change [B = –1.870; SE = 0.935 Wald = 4.003; d.f. = 1; p = 0.045; 
Exp(B)  =  0.154]. Parameter estimates of the final model 
(χ2 = 9.31296; d.f. = 2; p = 0.00951) are displayed in Table 4.
We performed the next step to simplify the model by only 
analyzing the direction of neurometabolite changes between two 
periods. Dichotomization of variables and inclusion of composite 
risk of concomitant Cho/Cr and NAA/Cr directions of changes 
after remission did not significantly improve the model. The final 
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subjects who entered a tapering-off period and (–0.3; SD = 1.6) 
in patients who experienced a recurrent episode later on, with no 
significant differences between those groups (p = 0.35).
DiscUssiOn
To our knowledge, this is the first study to identify 1H-MRS 
correlates of risk of a subsequent depressive episode while on 
maintenance therapy in the recovery phase. We demonstrated 
that a decreased Cho/Cr ratio at the beginning of recovery is 
predictive of depression recurrence in patients on maintenance 
therapy. Decreased Cho/Cr was associated with a 2.7-fold risk 
(95% CI: 1.12, 6.68) for a recurrent episode. Our results also 
suggest that decreases in Cho/Cr and NAA/Cr ratios after recov-
ery are related to a higher risk of the recurrent episode during 
maintenance therapy. Those risks persisted 6 months after index 
episode remission without a time-varying effect. Therefore, the 
observed findings could not be attributed to imminent worsen-
ing of patient’s condition that would closely follow decreases in 
Cho and NAA. In reviewing our results, we were faced with the 
difficulty of not being able to locate similar studies to directly 
compare our results.
NAA/Cr increases in frontal brain regions after SSRI therapy 
were previously reported (11, 13), which is in agreement with our 
findings. Most studies assessed patients until remission or soon 
after, but none followed up patients after recovery was achieved. 
Although the direction of NAA change is concordant with 
previous findings, the notable result is that NAA continued to 
rise in the favorable response group after recovery and remission 
while the patients continued pharmacotherapy. This could be of 
particular importance for future neuroplasticity studies.
Proton magnetic resonance spectroscopy research has 
provided relatively clear evidence about Cho increases in MDD 
patients (28, 29). We expected to observe a change in Cho; how-
ever, that hypothesis was based on consistent findings of increased 
Cho preceding the recovery phase. Intriguingly, the results 
indicate an increased membrane turnover rate in the DLPFC of 
non-recurrent patients. The observed ratio could presumably be 
consequent to PC-to-GPC mediated synthesis-to-breakdown 
overbalance, a finding congruent with the amygdala-to-DLPFC 
functional connectivity shift observed in neuroimaging studies.
When our finding of a continued Cho rise after the recovery 
phase was viewed together with NAA changes, there was ground 
for assuming a longer-term medication-induced neuroprotective 
effect. As symptom severity after recovery remained relatively 
stable, it is of particular importance that this postulated effect did 
not closely mirror clinical features. The combined increase of a 
marker of neuronal integrity (NAA) and a marker of membrane 
turnover (Cho) in non-recurrent patients points in the same 
direction as functional imaging studies showing that initial 
hypoactivity in the DLPFC of depressed patients turns to hyper-
activity in response to treatment (28). It could also be speculated 
that neuronal degeneration, as demonstrated by neuronal loss in 
cross-sectional and longitudinal structural MR studies in depres-
sion, may be reversible, at least on a microstructural level.
Our results show that brain metabolic changes occur beyond 
the acute treatment and remission phases. In practical terms, that 
means metabolic changes continue for at least 6  months after 
substance exposure started. We do not have any clear assumption 
regarding how long those changes will continue, but this certainly 
warrants longer-term MRS studies.
Patients who converted to bipolar disorder were entered into 
the analysis, despite our awareness that they do not belong to 
the recurrent depression population. The rationale for this 
is that no patient in our analysis was followed up indefinitely, so 
a potential conversion to bipolar disorder could not be excluded 
for any single patient. We considered that this approach ensures 
sample homogeneity in the analysis, as the population of interest 
was patients with documented recurrent depression at the time 
of the index episode. By excluding bipolar patients, we would 
superimpose future knowledge to historical time points.
Due to a limited range of episode severity in our sample, we 
could not perform assay analysis to assess the degree to which 
observed metabolite changes are influenced by the baseline sever-
ity of an episode. We also did not include some other identified 
risk factors of recurrence, such as family history of recurrent 
depression, previous history of dysthymic disorder, and residual 
depressive symptoms prior to the current episode, as we consider 
that information is not fully reliable when sourced from a patient 
rather than medical documentation.
The retrospective design is a drawback of our study. Repeating 
the analysis prospectively could improve sample stratification 
and allow the inclusion of more detailed assessment instruments. 
Ideally, subject MRS evaluation would be performed at baseline, 
before therapy initiation, at remission, and throughout recov-
ery. More scans would be helpful to eliminate the influence of 
temporal fluctuations, and would therefore improve the model’s 
sensitivity and specificity. With regards to the latter, although 
our sample size was relatively large for an MRS study, it was 
still underpowered to depict meaningful clinical sensitivity and 
specificity. Furthermore, the risk of type II error could not be 
eliminated, so repeated studies with similar design are certainly 
needed.
An important limitation of our study is that patients received 
different pharmacological treatments. It was only designed to 
correlate neurochemicals with clinical features, and no direct 
inference could be made to a specific antidepressant class. Current 
knowledge on subclass and substance-specific effects on clinical 
features is limited, and the evidence is even weaker for in vivo 
neurochemical levels. However, such effects exist, as clearly 
demonstrated in a report of the opposite effects of escitalopram 
and reboxetine in healthy subjects (30).
The formal definition of recovery is rather imprecise, which 
limits the possibility of generalizing our results to a specific tem-
poral pattern. Still, our primary aim was to investigate whether 
brain metabolite changes near the remission period delineate the 
future course of the depressive episode. This is obviously the case, 
but there is a need to clarify whether Cho and NAA changes are 
directly related to pathophysiological processes determining the 
course of the disorder or if they are only indirect correlates.
In the longer term, identifying the prognostic correlates of the 
disorder’s course is important to delineate the neurophysiological 
background of depressive disorder and possibly improve patient 
wellbeing by reducing the risk of recurrent episodes.
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Research of 1H-MRS metabolite changes over a longer 
recovery phase is required to provide more detailed insight into 
the relationships of measurable 1H-MRS metabolites as putative 
markers of the longitudinal course of the depressive disorder. 
Our findings support the notion of other researchers (28) that 
targeting neural plasticity in depression may lead to treatment 
breakthroughs.
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